Fascia Iliaca Blocks and Pre-operative Opioid Requirements in Hip Fracture Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02804542|
Recruitment Status : Unknown
Verified January 2018 by Spectrum Health Hospitals.
Recruitment status was: Enrolling by invitation
First Posted : June 17, 2016
Last Update Posted : January 11, 2018
|Condition or disease||Intervention/treatment|
|Hip Fracture||Other: Observational Other: Retrospective review|
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||Pre-operative Fascia Iliaca Blocks and Opioid Requirements in Hip Fracture Patients|
|Actual Study Start Date :||August 11, 2016|
|Estimated Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||August 2018|
Fascia Iliaca Block Cohort
Prospective patients receiving fascia iliaca blocks A prospective Observational study of Hip fracture patients that are offered fascia iliaca blocks as standard of care in the ED.
Retrospective Control Cohort
No fascia iliaca block performed A retrospective review will be done of hip fracture patients that did not receive fascia iliaca blocks (before fascia iliaca blocks being offered in the ED as standard of care).
Other: Retrospective review
- Total Pre-op IV Morphine Equivalents (TIVME) [ Time Frame: From Date of admission until date of surgery, approximately 48 hours ]IV morphine equivalent dosing pre-operatively
- Mean Pre-op Pain Score [ Time Frame: From Date of admission until date of surgery, approximately 48 hours ]Mean patient-reported pain score
- Length of Hospital Stay (LOS) [ Time Frame: Through study completion, approximately 5 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02804542
|Principal Investigator:||Matthew Flannigan, MD||ECS|